Steve Duffy

3 days ago | dermatologyadvisor.com | Steve Duffy

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. DrugPharmacologic ClassProposed IndicationStatusCardiovascular DiseaseSemaglutide (Novo Nordisk)Glucagon-like peptide-1 receptor agonistTo improve walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

3 days ago | pulmonologyadvisor.com | Steve Duffy

DrugPharmacologic ClassIndicationMore InformationAllergic DisordersDupixent (dupilumab)Interleukin-4 receptor alpha antagonistTreatment of patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.

5 days ago | empr.com | Steve Duffy

New epinephrine nasal spray dosage approved for pediatrics; FDA agree to review semaglutide for weight management; wearable defibrillator cleared to prevent sudden cardiac arrest; a low dose formulation of chlorthalidone is approved to treat hypertension; and Selarsdi is now interchangeable with Stelara.

6 days ago | rheumatologyadvisor.com | Steve Duffy

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. DrugPharmacologic ClassProposed IndicationStatusCardiovascular DiseaseSemaglutide (Novo Nordisk)Glucagon-like peptide-1 receptor agonistTo improve walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

6 days ago | dermatologyadvisor.com | Steve Duffy

DrugPharmacologic ClassIndicationMore InformationAllergic DisordersDupixent (dupilumab)Interleukin-4 receptor alpha antagonistTreatment of patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.